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summary: Despite health gains achieved through rotavirus vaccination, rotavirus remains 
the most common cause of severe, hospitalised diarrhoea among children in Malawi. There 
is a pressing need to identify strategies to improve rotavirus vaccine performance in high 
disease burden, low-income countries.” 
 
ABSTRACT 
Despite rotavirus vaccination, diarrhoea remains a leading cause of child mortality. We collected 
stool from 684 children <5 years of age hospitalised with diarrhoea (cases) and 527 asymptomatic 
community controls, for four years post rotavirus vaccine introduction in Malawi, and examined for 
29 pathogens using PCR. Three or more pathogens were detected in 71% of cases and 48% of 
controls. Pathogens significantly associated with diarrhoea (cases/controls) included rotavirus 
(34.7%/1.5%), enteric adenovirus (29.1%/2.7%), Cryptosporidium (27.8%/8.2%), heat-stable 
enterotoxin-producing E.coli (21.2%/8.5%), typical enteropathogenic E.coli (18.0%/8.3%), and 
Shigella/enteroinvasive E.coli (15.8%/5.7%). Additional interventions are required to prevent 
diarrhoea due to rotavirus and other leading pathogens.  
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BACKGROUND 
The introduction of rotavirus vaccines into childhood immunisation programmes across Africa has 
reduced rotavirus hospitalisations, with a recent population-based study from Malawi providing the 
first evidence of vaccine impact on infant diarrhoeal deaths [1]. However, the contribution of other 
viral, bacterial, and parasitic causes of diarrhoea among rotavirus-vaccinated African populations is 
not well understood [2,3]. 
Malawi is a low-income country in sub-Saharan Africa with one of the highest adult prevalence rates 
for HIV/AIDS, globally; 17.8% of women 15-49 years of age living in urban Malawi are HIV-infected 
(https://dhsprogram.com/pubs/pdf/SR237/SR237.pdf).  
In children under 5 years of age, the mortality rate is 55 per 1000 live births with a high prevalence 
of stunting (37%). At the Malawi-Liverpool-Wellcome Trust Clinical Research Programme in Blantyre, 
Malawi, we have examined the effectiveness against hospitalised rotavirus diarrhoea of monovalent 
human rotavirus vaccine [Rotarix®], which was introduced into Malawi’s national immunisation 
schedule in October 2012 [4]. Our diarrhoea surveillance platform is centred on a large urban 
hospital (Queen Elizabeth Central Hospital, QECH) and includes collection of clinical, demographic, 
and socioeconomic data combined with documentation of rotavirus vaccine status and stool 
collection. 
We aimed to understand the aetiology of severe acute childhood gastroenteritis following rotavirus 
vaccine introduction in Malawi. We therefore undertook a case-control study to examine the 
prevalence of enteric pathogens among hospitalised children <5 years of age with diarrhoea, 
compared to diarrhoea-free children in the community. 
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METHODS  
Study setting 
The study was conducted in Blantyre, a district in Southern Malawi with a population of 
approximately 1.3 million people. The QECH provides free healthcare to residents of urban and rural 
areas of Blantyre district and is the only free/government inpatient referral centre in Southern 
Malawi. Monovalent rotavirus vaccine is administered according to the WHO-recommended 
schedule of 6 and 10 weeks. Vaccine coverage increased rapidly following introduction, and has 
exceeded 90% among age-eligible children since 2014 [1,5].  
Symptomatic hospitalised cases  
Subject enrolment and specimen collection was undertaken as part of our existing research 
programme [4]. Stool specimens were collected from November 2012 to December 2015 from 
children <5 years of age with acute gastroenteritis admitted to QECH (cases). Acute gastroenteritis 
was defined as the passage of three or more loose stools within a 24-hour period commencing <14 
days prior to enrolment. We obtained demographic, clinical, and anthropometric data through 
parental interview, physical examination, and review of medical notes. Maternal HIV testing was 
undertaken according to national guidelines, as previously reported [4]. Disease severity was 
measured using the Vesikari score; a score of ≥11 (out of 20) indicates severe disease.  
Asymptomatic community controls   
Stool specimens were collected from children in the community who reported no diarrhoea for at 
least 7 days. These comprised a random sample of community controls recruited between April 2013 
and December 2016 into rotavirus vaccine effectiveness case-control studies, in which controls were 
matched to individual rotavirus confirmed cases by age- and district-of-residence [4,5].  .  
Laboratory testing 
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Faecal specimens were stored at -80OC. We tested for 29 different enteric pathogens in faecal 
specimens using a 384-well singleplex real-time PCR platform, the enteric Taqman Array Cards (TAC) 
[6]. The TAC method performance has been previously described; samples were classified as 
pathogen positive at a cycle threshold (CT) of <35 [6]. Detection above this threshold is not 
reproducible and is unlikely to be clinically significant [6]. 
Analysis 
Since the introduction of rotavirus vaccination, norovirus has gained increasing recognition as a 
significant pathogen associated with diarrhoea in children [7]. We therefore based our sample size 
calculation on norovirus prevalence. Assuming a prevalence of 10% among hospitalised 
gastroenteritis cases and 5% among asymptomatic community controls [8], we calculated that for 
90% power, 621 samples per group were needed to show a significant difference in prevalence 
between cases and controls (α=0.05). Pathogen prevalence among cases and controls was compared 
using χ2-test or Fisher’s exact test. Differences between continuous variables were tested using 
Student’s t-test or Wilcoxon rank-sum test. 
Adjusted attributable fractions (AFs) were calculated for pathogens which had a greater prevalence 
in cases compared to controls. Using a similar approach to the Global Enteric Multicentre Study 
(GEMS) [9], multivariable logistic regression was used to calculate odds ratios (ORs) for each 
pathogen detected, adjusting for presence of other pathogens, age in months and month of 
recruitment. Case or control status was the outcome variable and the predictors were indicator 
variables representing the presence or absence of each pathogen. We then calculated AFs for 
pathogens that were significant (p<0.05) in multivariable logistic regression. Calculation of AFs 
follows the formula:   
       (  
 
   
) 
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where   = prevalence of pathogen   among cases. Analyses were performed using R version 3.3.5 (R 
Development Core Team, Vienna, Austria), with AFs and associated confidence intervals (CIs) 
calculated using bootstrap resampling in the ‘attribrisk’ package.  
Ethics  
Approval was obtained from the Malawi National Health Sciences Research Committee (Protocol 
#837) and from the University of Liverpool Research Ethics Committee (RETH #490).   
RESULTS  
Study population  
A total of 1,211 faecal samples were analysed, comprising 684 samples from symptomatic 
hospitalised cases and 527 samples from asymptomatic community controls (Supplementary Table 
1). Median age was 10.7 months (IQR: 7.9-15.4) and 12 months (IQR: 9.2-18.7) for cases and 
controls, respectively. Rotavirus vaccine status was established for 419/451 vaccine age-eligible 
cases (of whom 97% had received one dose or more), and in 375/400 vaccine age-eligible controls 
(of whom 95% were vaccinated). Maternal HIV status was determined for 665 (97%) of 684 cases, of 
whom 18% were HIV exposed. Mid-upper arm circumference (MUAC) was lower in cases 
(median=13.0 cm) compared with controls (median=15.3 cm). Among cases, 60 (9%) were severely 
malnourished (MUAC<11.5cm) compared with two (0.4%) controls. Vesikari score among cases 
ranged from mild (score of 1) to very severe (score of 20) (Median=13; IQR 10-15).  
Pathogen prevalence  
A positive PCR result for at least one pathogen was returned in 641 samples (94%) from cases and in 
390 (74%) from controls (p<0.001) (Supplementary Table 1). Pathogens that were more frequently 
identified in cases than in controls included, in decreasing order of prevalence (cases/controls): 
rotavirus (34.7%/1.5%), adenovirus 40/41 (29.1%/2.7%), Cryptosporidium (27.8%/8.2%), heat-stable 
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enterotoxin-producing E.coli ([ST-ETEC] 21.2%/8.5%), typical enteropathogenic E.coli ([typical 
EPEC]18.0%/8.3%), Shigella/enteroinvasive E. coli (EIEC) (15.8%/5.7%), Salmonella typhimurium 
(2.3%/0.4%) and Vibrio cholerae (1.3%/0%) (Table 1). Pathogen prevalence by age group is presented 
in Supplementary Table 2. Giardia was less frequently detected in cases compared with controls 
(7.3%/13.9%). Enteroaggregative E. coli (EAEC), Campylobacter and norovirus were frequently 
detected in both cases and controls. Pathogens with the highest AFs ascribed to them were 
rotavirus, adenovirus 40/41 and Cryptosporidium (Table 1). Median Vesikari scores by pathogen 
ranged from 11 to 14.5 (Supplementary Figure 1).  
Pathogen age distribution  
The median age of Giardia-positive cases (15.6 months) was significantly higher compared to 
Giardia-positive controls (11.7 months) (p=0.014). For Campylobacter (10.9 (in cases)/13.8 (in 
controls) months: p<0.001), LT-ETEC (10.8/12.0 months: p=0.044) and atypical EPEC (11.3/12.4 
months: p=0.030), median age of cases was significantly lower compared to controls. There was no 
difference in age between cases and controls for the remaining pathogens (Supplementary Figure 2). 
Mixed infections  
Among  pathogen-positive samples, a single pathogen was detected in 78 (11%) and in 42 (8%) of 
samples from cases and controls, respectively. Cases had a significantly higher number of pathogens 
(mean=3.65,   =2.11) compared to controls (mean=2.42, SD=1.96), with three or more pathogens 
detected in 71% of cases compared with 48% of controls. Enteroaggregative E.coli (EAEC) was 
identified in 51.8% of cases and in 47.8% of controls. The most frequent co-infections involving EAEC 
were with rotavirus, adenovirus 40/41, Cryptosporidium, ST-ETEC and typical EPEC among diarrhoea 
cases; and with Campylobacter, atypical EPEC, Giardia, and LT-ETEC among asymptomatic controls 
(Figure 1). 
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DISCUSSION 
We have shown that following rotavirus vaccine introduction in Malawi, rotavirus remains the 
leading pathogen detected in children <5 years of age hospitalised due to diarrhoea. This is in 
agreement with data from two smaller studies, including one in Tanzania that assessed 146 
diarrhoea cases in 2015, and another reported by the Global Rotavirus Surveillance Network (GRSN) 
that analysed a total of 327 samples collected from 10 African countries between 2013 and 2014 
[2,3]. The prevalence of rotavirus shedding in asymptomatic children reported in this study (1.5%) is 
lower than reported previously in Malawi [10]. This may be the consequence of high rotavirus 
vaccine coverage reducing community rotavirus transmission, and could potentially lead to indirect 
benefits [5].  
Adenovirus 40/41 was significantly associated with diarrhoea hospitalisation, in contrast with data 
from Tanzania and the GRSN that reported a modest AF for this pathogen [2,3]; however, the AFs 
calculated by these studies relied upon asymptomatic community samples collected by the GEMS 
study prior to rotavirus vaccine introduction [9]. Furthermore, pathogen-specific AFs should be 
interpreted with caution, since the relationship between organism load, disease severity and 
duration of shedding are not well defined for pathogens other than rotavirus. Nevertheless, the high 
prevalence of adenovirus 40/41 in cases, combined with a low prevalence in asymptomatic children, 
suggests an important role for this pathogen in severe diarrhoea in Malawian children. Our data are 
supported by recent reanalysis of the GEMS and MAL-ED (The Aetiology, Risk Factors, and 
Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health) studies, 
which highlighted the importance of adenovirus 40/41 among children with diarrhoea [11,12].  
Cryptosporidium was frequently associated with hospitalised diarrhoea in Malawian children, with a 
higher prevalence than reported in studies conducted elsewhere [2,3,9,11,12]. Cryptosporidium 
diarrhoea is associated with 4.2 million disability-adjusted life-years (DALYs) lost globally, and 7.85 
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million DALYs after accounting for the negative impact it has on growth [13]. These data highlight the 
need to prioritise effective treatment and prevention of Cryptosporidium infection in Malawi and 
other low-income countries that have high rates of stunting and HIV/AIDS, in order to reduce the 
burden of diarrhoeal disease and its associated long-term health consequences. 
We also identified ST-ETEC, typical EPEC and Shigella/EIEC as important pathogens associated with 
hospitalised diarrhoeal disease, in line with previous reports [2,11,12]. Other pathogenic E. coli were 
also commonly detected. EAEC was found in nearly half of the infants regardless of presence of 
diarrhoea, and was frequently identified in co-infections among both cases and controls. Although 
EAEC does not appear to be associated with acute diarrhoea in this or previous studies [2,3,9], its 
presence with two or more other pathogens may have a negative impact on infant growth [14]. 
Similarly, despite a lack of association with hospitalised diarrhoea, the high prevalence of 
Campylobacter and Giardia in asymptomatic children in Malawi may result in growth faltering [15]. 
In some high-income settings, norovirus has emerged as the leading cause of severe diarrhoea in 
children following rotavirus vaccine introduction [14]. However, we did not document any change in 
norovirus prevalence since rotavirus vaccine introduction in Malawi; norovirus was identified in 
12.1% of children hospitalized with diarrhoea compared to 11.3% in the pre-vaccine period [15].  
Our study has limitations. Firstly, cases were slightly younger than controls; we therefore adjusted 
for age and month of recruitment in the analyses. We calculated AFs based on the binary presence 
or absence of pathogens, similar to the original GEMS study [9]. This method differs from those used 
for the reanalysis of GEMS and MAL-ED studies [12,15], where pathogen quantity was included in 
the model as a quadratic term. We chose not to use this approach because, unlike longitudinal 
studies, the duration of pathogen shedding is not quantifiable in case-control studies, and pathogen 
quantity will be variably associated with disease. A further consideration is our inclusion of cases 
from Nov 2012 to March 2013 prior to control recruitment, in order to achieve the required sample 
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size.  In sensitivity analysis, excluding the early cases did not significantly alter the point prevalence 
of any pathogen (data not shown). 
Rotavirus remains the most common cause of severe, hospitalised diarrhoea among children in 
Malawi, highlighting the importance of identifying strategies to improve rotavirus vaccine 
performance in this and similar high disease burden, low-income countries. Adenovirus 40/41, 
Cryptosporidium, ST-ETEC, typical EPEC and Shigella/EIEC are significant additional contributors to 
the burden of gastrointestinal disease in this population. Public health efforts, including vaccine 
development, should target these pathogens.  
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Figure 1: Pairwise co-infections in hospitalised diarrhoea cases and asymptomatic community 
controls. Percentage of infections is shown and was calculated by dividing the number of infections with both pathogen 
A (row) and B (column) by the denominator for the relevant group (i.e either total cases or total controls). 
EAEC=Enteroaggregative E. coli. EIEC=enteroinvasive E.coli. EPEC=enteropathogenic E.coli.LT-ETEC=heat-labile enterotoxin-
producing E.coli. ST-ETEC=STh or STp-producing enterotoxigenic E.coli. STEC= shiga toxin-producing E.coli.  
 
 
  
Symptomatic cases (n=684) 
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Table 1: Prevalence and attributable fractions of enteric pathogens in hospitalised diarrhoea cases 
and asymptomatic community controls. Pathogens are listed in order of decreasing prevalence 
among cases.  
 
Cases 
n=684 (%)  
Controls 
n=527 (%) 
p-value AF SE CI 
EAEC 354 (51.8) 252 (47.8) 0.193    
Rotavirus 237 (34.6) 8 (1.5) <0.001 34.2% 0.018 (31.1-38.0) 
Adenovirus 40/41 199 (29.1) 14 (2.7) <0.001 27.7% 0.018 (24.5-31.4) 
Cryptosporidium 190 (27.8) 43 (8.2) <0.001 22.3% 0.023 (18.2-27.2) 
ST-ETEC 145 (21.2) 45 (8.5) <0.001 12.7% 0.030 (7.2-18.1) 
Typical EPEC 123 (18.0) 44 (8.3) <0.001 6.6% 0.037 
(0-12.2) 
Campylobacter any 113 (16.5) 102 (19.4) 0.229   
 
Shigella/EIEC 108 (15.8) 30 (5.7) <0.001 10.8% 0.021 
(6.5-14.9) 
Norovirus  83 (12.1) 45 (8.5) 0.054 7.0% 0.019 
(2.8-10.6) 
atypical EPEC 77 (11.3) 80 (15.2) 0.054    
LT-ETEC 68 (9.9) 71 (13.5) 0.069    
Sapovirus 64 (9.4) 34 (6.5) 0.083    
Giardia 50 (7.3) 73 (13.9) <0.001    
Enterocytozoon bieneusi 31 (4.5) 21 (4.0) 0.747    
Salmonella any 30 (4.4) 5 (0.9) 0.001    
Aeromonas  27 (3.9) 10 (1.9) 0.059    
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Salmonella Typhimurium 16 (2.3) 2 (0.4) 0.007 1.8% 0.009 (0.0-3.2) 
Encephalitozoon intestinalis 15 (2.2) 20 (3.8) 0.14    
Cyclospora 13 (1.9) 4 (0.8) 0.138    
Astrovirus  12 (1.8) 13 (2.5) 0.509    
Entamoeba histolytica 10 (1.5) 8 (1.5) 1    
Vibrio cholerae 9 (1.3) 0 (0.0) 0.006    
Salmonella Typhi 8 (1.2) 2 (0.4) 0.201    
Strongyloides   7 (1.3) 10 (1.5) 0.845    
Necator 5 (0.7) 1 (0.2) 0.241    
STEC 5 (0.7) 1 (0.2) 0.241    
Ascaris 4 (0.6) 5 (0.9) 0.514    
Isospora 3 (0.4) 1 (0.2) 0.637    
Salmonella Enteritidis 0 (0.0) 0 (0.0) NA    
Trichuris 0 (0.0) 1 (0.2) 0.435    
Ancyclostoma 0 (0.0) 0 (0.0) NA    
Ancyclostoma, Salmonella Enteritidis and Trichuris were not included in the analysis because they not detected in either 
cases or controls. AF=adjusted attributable fraction; SE=standard error; LCI=lower confidence interval; UCI=upper 
confidence interval; EAEC=Enteroaggregative E. coli; EIEC=enteroinvasive E.coli; EPEC=enteropathogenic E.coli.LT-
ETEC=heat-labile enterotoxin-producing E.coli; ST-ETEC=STh or STp-producing enterotoxigenic E.coli; STEC= shiga toxin-
producing E.coli. 
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